ScholarLens Back to search
2013•Journal for ImmunoTherapy of CancerOpen access

Immune correlates of metastatic melanoma patients treated with ipilimumab in combination with fotemustine in the phase II NIBIT-M1 study

Cristina Maccalli, Hugues J. M. Nicolay, Filippo Capocefalo, Ester Fonsatti, Carla Chiarucci, Ornella Cutaia, Diana Giannarelli, Giorgio Parmiani, Anna Maria Di Giacomo, Michele Maio

Open full text 0 citations

Abstract

Meeting abstracts Ipilimumab (IPI) in combination with fotemustine (FTM) has shown a promising clinical activity in metastatic melanoma (MM) patients (pts) enrolled in the NIBIT-M1 trial (Di Giacomo, et al., Lancet Oncology, 2012). This study investigated changes in immunological parameters in the

Open-access reader

About this research paper

What this paper is about

Meeting abstracts Ipilimumab (IPI) in combination with fotemustine (FTM) has shown a promising clinical activity in metastatic melanoma (MM) patients (pts) enrolled in the NIBIT-M1 trial (Di Giacomo, et al., Lancet Oncology, 2012). This study investigated changes in immunological parameters in the

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Meeting abstracts Ipilimumab (IPI) in combination with fotemustine (FTM) has shown a promising clinical activity in metastatic melanoma (MM) patients (pts) enrolled in the NIBIT-M1 trial (Di Giacomo, et al., Lancet Oncology, 2012). This study investigated changes in immunological parameters in the

Key concepts: Ipilimumab, Metastatic melanoma, Medicine, Internal medicine, Melanoma, Oncology, Clinical trial, Immunotherapy

Related papers

Related paper 1Related paper 2
Back to paper searchBrowse research topicsOriginal source
Immune correlates of metastatic melanoma patients treated with ipilimumab in combination with fotemustine in the phase II NIBIT-M1 study — Research Paper | ScholarLens